Promising Future for Silexion Therapeutics: Buy Rating Reiterated Due to SIL-204’s Potential in KRAS-Mutated Cancers

Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Silexion Therapeutics (SLXN – Research Report). The associated price target remains the same with $5.00.

Naz Rahman has given his Buy rating due to a combination of factors that highlight Silexion Therapeutics’ promising future. The company is advancing its lead candidate, SIL-204, which targets KRAS mutations in non-resectable, locally advanced pancreatic cancer, into Phase 2b/3 studies. Recent preclinical data has shown that SIL-204 exhibits anti-tumor activity in additional cancers such as colorectal and lung cancers, which also harbor KRAS mutations. This suggests a potential expansion of SIL-204’s application beyond pancreatic cancer, potentially increasing its market opportunity.
Although the data is in early stages, the results are promising, indicating a significant commercial potential for SIL-204 in treating various KRAS-mutated cancers. Silexion’s focus on developing SIL-204 for pancreatic cancer, along with ongoing toxicology studies and regulatory meetings, positions the company well for future growth. The global treatment market for KRAS-mutated cancers is substantial, and the promising data supports further development of SIL-204 into additional indications, which could meaningfully enhance Silexion’s market reach. Therefore, Rahman reiterates a Buy rating, considering the promising data and potential market expansion.